Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment

Core Insights - Liquidia Corp. (NASDAQ:LQDA) has shown significant stock performance, rising by 10.67% to close at $27.91, nearing its 52-week high due to strong demand for its pulmonary hypertension treatment [1][3]. Financial Performance - In Q3, Liquidia reported total revenues of $54 million, a remarkable increase of 1,134% from $4.4 million in the same period last year, driven primarily by the sales of its Yutrepia treatment [2][3]. - Product sales contributed $51.7 million to the total revenues, while service revenues accounted for $2.67 million [3]. - The company managed to reduce its net loss by 89% to $3.5 million from $31.03 million in the comparable period last year [3]. Market Demand and Growth Strategy - The CEO of Liquidia highlighted the strong momentum of Yutrepia's launch, noting over 2,000 unique prescriptions and shipments to more than 1,500 patients, supported by over 600 prescribers nationwide as of October 30, 2025 [4]. - The company is positioned for sustained growth and profitability, with plans to invest in expanding Yutrepia's therapeutic profile and advancing L606 into pivotal trials [5].